Xencor, Inc Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Xencor, Inc (XNCR) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-08-05
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-06-30 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-03-31 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-09-30 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-30 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2025 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 0.00 shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-25 | |||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 0.00 shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-25 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 0.00 shares 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-06 | 0.00 shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-25 | |||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | 0.00 shares 10-K/A · filed 2025-02-24 | |||
| 2022-03-31 | 1.67M shares 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 2.12M shares 10-K/A · filed 2025-02-24 | |||
| 2021-09-30 | 2.15M shares 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | 2.09M shares 10-Q · filed 2022-08-03 | 2.38M shares 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-02-27 | |||
| 2019-12-31 | 1.94M shares 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 1.92M shares 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | 1.69M shares 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | 1.71M shares 10-Q · filed 2020-05-08 | |||
| 2016-12-31 | 1.12M shares 10-K · filed 2019-02-26 | |||
| 2016-09-30 | 1.05M shares 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | 937.87K shares 10-Q · filed 2017-08-07 | 997.57K shares 10-Q · filed 2017-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |